| Literature DB >> 29190943 |
Haobin Cai1,2, Yijie Wang1, Jiayang He1, Tiantian Cai1, Jun Wu1, Jiansong Fang1, Rong Zhang1, Zhouke Guo2, Li Guan1, Qinkai Zhan1, Li Lin3, Yao Xiao4, Huafeng Pan1, Qi Wang1.
Abstract
Alzheimer's disease (AD) is a progressive neurological degenerative disease. The main clinical manifestations of AD include progressive cognitive impairment and alteration of personality. Senile plaques, neuroinflammation, and destruction of synapse structure stability are the main pathological features of AD. Bajijiasu(BJJS) is extracted from Morinda Officinalis, a Chinese herb. In this study, we explored the effect of BJJS on AD from many aspects in APPswe/PSEN1ΔE9 (APP/PS1) double transgenic mice. The Morris water maze and novel object recognition tests results showed that BJJS could significantly improve the learning and memory abilities in APP/PS1 mice. BJJS treatment increased the level of insulin degradation enzyme (IDE) and neprilysin (NEP) and decreased the level of β-site app cleaving enzyme 1(BACE1) in the brain of APP/PS1 mice. BJJS-treated APP/PS1 mice appeared to have reductions of Aβ deposition and senile plaques, and showed higher levels of neurotrophic factors in the brain. We also found that BJJS had an inhibitory function on neuroinflammation in APP/PS1 mice. In addition, the synapse structure relevant proteins were elevated in the brain of BJJS-treated APP/PS1 mice. The present results indicated that BJJS could attenuate cognitive impairment via ameliorating the AD-related pathological alterations in APP/PS1 mice. These findings suggest that BJJS may be a potential therapeutic strategy in Alzheimer's disease.Entities:
Keywords: APP/PS1 mice; amyloid-β; bajijiasu; cognitive impairment; dementia
Year: 2017 PMID: 29190943 PMCID: PMC5696209 DOI: 10.18632/oncotarget.21515
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Figure 1BJJS improved the learning and memory abilities in APP/PS1 mice
(A) Escape latencies in water maze during the positioning navigation test. (B) Crossing times of the platform location during the probe trial. (C, D) Time spent in the target quadrant and in the opposite quadrant during the probe trial. (E) Representative tracings of the animal's path during the positioning navigation test. (F) The partial index on the third day of the novel object recognition test. (G) The discrimination index on the third day of the novel object recognition test. Data are shown as the mean ± SEM (n=10 mice per group). # P<0.05 and ## P<0.01 versus the wild-type group. * P<0.05 and ** P<0.01 versus the APP/PS1 group.
Figure 2BJJS attenuated amyloid-β generation and deposition in APP/PS1 mice
(A, B) The levels of proteins associated with amyloid-β metabolism in the hippocampus. (C, D) The levels of proteins associated with amyloid-β metabolism in the cortex. (E) The level of Aβ1-42 in the hippocampus. (F) The level of Aβ1-42 in the cortex. (G, H) Representative images and quantitative graph for Thioflavin-S staining in the brain of APP/PS1 mice. Data are shown as the mean ± SEM (n=10 mice per group). # P<0.05 and ## P<0.01 versus the wild-type group. * P<0.05 and ** P<0.01 versus the APP/PS1 group.
Figure 3BJJS enhanced the expression level of neurotrophic factors in APP/PS1 mice
(A, B) The levels of BDNF and NGF in the hippocampus. (C, D) The levels of BDNF and NGF in the cortex. Data are shown as the mean ± SEM (n=10 mice per group). # P<0.05 and ## P<0.01 versus the wild-type group. * P<0.05 and ** P<0.01 versus the APP/PS1 group.
Figure 4Inhibitory function of BJJS on neuroinflammation in APP/PS1 mice
(A, B) The levels of nuclear transcription factor-kappa B in the hippocampus. (C, D) The levels of nuclear transcription factor-kappa B in the cortex. (E) The levels of tumor necrosis factor-α in the cortex. (F) The levels of interleukin- β in the cortex. (G, H) The levels of microglial markers Iba1 and CD40 in the cortex. Data are shown as the mean ± SEM (n=10 mice per group). # P<0.05 and ## P<0.01 versus the wild-type group. * P<0.05 and ** P<0.01 versus the APP/PS1 group.
Figure 5BJJS elevated synapse structure relevant proteins in APP/PS1 mice
(A, B) The levels of proteins associated with synapse structure stability in the hippocampus. (C, D) The levels of proteins associated with synapse structure stability in the cortex. Data are shown as the mean ± SEM (n=10 mice per group). # P<0.05 and ## P<0.01 versus the wild-type group. * P<0.05 and ** P<0.01 versus the APP/PS1 group.